Breaking Short Interest: What’s Propelling Venaxis Incorporated (NASDAQ:APPY) After Higher Shorts Reported?

November 24, 2016 - By Dolores Ford   ·   0 Comments

Breaking Short Interest: What’s Propelling Venaxis Incorporated (NASDAQ:APPY) After Higher Shorts Reported?

The stock of Venaxis Incorporated (NASDAQ:APPY) registered an increase of 53.33% in short interest. APPY’s total short interest was 23,000 shares in November as published by FINRA. Its up 53.33% from 15,000 shares, reported previously. With 13,800 shares average volume, it will take short sellers 2 days to cover their APPY’s short positions. The short interest to Venaxis Incorporated’s float is 0.7%. The stock decreased 2.48% or $0.07 on November 23, hitting $2.75. About 8,403 shares traded hands. Venaxis Inc (NASDAQ:APPY) has declined 10.42% since April 22, 2016 and is downtrending. It has underperformed by 15.83% the S&P500.

Venaxis, Inc. is an in vitro diagnostic firm that is focused on commercializing its blood test to serve as an adjunctive test in the diagnosis and treatment of acute appendicitis in children, adolescent and young adults. The company has a market cap of $12.08 million. The Company’s test, the APPY1 Test, is a blood test panel for aiding in identifying patients in the emergency department that are at low risk for acute appendicitis. It currently has negative earnings. The APPY1 System consists of a small fluorometer (APPYReader Instrument) and consumable test products (APPYReader QC Cassette, APPY1 Controls and APPY1 Test).

APPY Company Profile

Venaxis, Inc. (Venaxis), incorporated on July 24, 2000, is an in vitro diagnostic firm that is focused on commercializing its blood test to serve as an adjunctive test in the diagnosis and treatment of acute appendicitis in children, adolescent and young adults. The Company’s test, the APPY1 Test, is a blood test panel for aiding in identifying patients in the emergency department that are at low risk for acute appendicitis. The APPY1 System consists of a small fluorometer (APPYReader Instrument) and consumable test products (APPYReader QC Cassette, APPY1 Controls and APPY1 Test). The APPYReader Instrument measures fluorescence from the APPY1 Test cassette and the APPYReader QC Cassette, the APPYReader QC Cassette enables for functioning of the APPYReader Instrument, and the APPY1 Controls enable functioning of the APPY1 Test components. The APPY1 Test combines the concentrations of approximately three analytes, such as white blood cell count (WBC), C-reactive protein (CRP) and Venaxis’ myeloid-related protein 8/14 (MRP 8/14), using an algorithm to provide a result to the physician to aid in the identification of patients at low risk for acute appendicitis.

More important recent Venaxis Inc (NASDAQ:APPY) news were published by: Prnewswire.com which released: “Venaxis Announces Acquisition of BiOptix” on September 13, 2016, also Quotes.Wsj.com published article titled: “Venaxis Inc. APPY (US: Nasdaq)”, Businesswire.com published: “INVESTOR ALERT: Class Action Lawsuit Against Venaxis, Inc. Announced By Glancy …” on February 18, 2015. More interesting news about Venaxis Inc (NASDAQ:APPY) was released by: Prnewswire.com and their article: “AspenBio Pharma Changes Company Name to Venaxis, Inc.” with publication date: December 12, 2012.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Dolores Ford


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>